• Press Office

    Posted in category ABPI statement by Press Office on 04/12/2013

    ABPI responds to Deloitte/Thomson Reuters report: Is life sciences R&D earning its investment?

The pharmaceutical industry is committed to developing new medicines to treat unmet medical needs.


​Whilst the Deloitte report concludes that it costs up to £1.2 billion to develop a new medicine the pharmaceutical industry is continuously innovating The industry is always seeking to enhance R&D productivity by using different approaches including open innovation, pre competitive collaboration, optimising data analytics, and placing an increased focus on stratified medicines, and real world R&D.

At the same time, innovative medicines demonstrated to be efficacious and cost-effective should be used by healthcare systems - benefiting patients and incentivising reinvestment into R&D.

Print this page icon Print this page
Please choose the subject of your enquiry from the list below:
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.